<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02436759</url>
  </required_header>
  <id_info>
    <org_study_id>RVL-1201-201</org_study_id>
    <nct_id>NCT02436759</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis</brief_title>
  <official_title>A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RVL Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RVL Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 study is to evaluate the safety and efficacy of RVL-1201 Ophthalmic&#xD;
      Solution in the treatment of acquired blepharoptosis (ptosis) and to assess the safety and&#xD;
      comfort of RVL-1201 Ophthalmic Solution for an extended dosing period of 6 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ptosis is experienced by approximately 12% of adults over the age of 50 . It is a unilateral&#xD;
      or bilateral abnormal drooping of the upper eyelid that usually occurs from a partial or&#xD;
      complete dysfunction of the muscle(s) that elevate the upper eyelid: the levator palpebrae&#xD;
      superioris and/or Müller's muscle.&#xD;
&#xD;
      Treatment for acquired ptosis usually involves surgery, with risks of infection, bleeding,&#xD;
      over or undercorrection, reduced vision, and lagophthalmos (inability to close the eyelids&#xD;
      completely) or mechanical treatment e.g scleral contact lenses with a bar to lift the eyelid,&#xD;
      eyelid ptosis crutches attached to glasses, or adhesive tape or putty to affix the upper&#xD;
      eyelid to the supraorbital structures.&#xD;
&#xD;
      RVL-201 ophthalmic solution is being developed to provide a reversible pharmacologic option&#xD;
      for patients with acquired ptosis who are not candidates for surgery or do not wish to&#xD;
      undergo surgery.&#xD;
&#xD;
      The objective of this study is to evaluate the safety and efficacy of RVL-1201 ophthalmic&#xD;
      solution in the treatment of acquired blepharoptosis and to assess the safety and comfort of&#xD;
      RVL-1201 ophthalmic solution for an extended dosing period of 6 weeks. Subjects will be&#xD;
      randomized (2:1) to one of 2 treatment arms and treated for 42 days:&#xD;
&#xD;
        -  RVL-1201 0.1% one full drop in each eye QD in the morning (N = 100)&#xD;
&#xD;
        -  RVL-1201 vehicle (placebo) 1 full drop per eye QD in the morning (N = 50)&#xD;
&#xD;
      Efficacy will be assessed with the LPFT, a validated visual field test using the HVF Analyzer&#xD;
      and photographic measurement of MRD (the distance from the pupillary light reflex to the&#xD;
      central margin of the upper lid) and PFD (the distance from the upper lid margin to the lower&#xD;
      lid margin through the central visual axis). Safety assessment will include bilateral&#xD;
      SLE/CFS, measurement of PD from external photographs, dilated ophthalmoscopy/fundus&#xD;
      examination, tonometry, Snellen VA using recent correction, vital signs (BP/HR), and&#xD;
      collection of adverse events (AEs).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group</measure>
    <time_frame>Mean change from Baseline (Day 1, Hour 0) compared with Day 1, Hour 6 and Day 14, Hour 2</time_frame>
    <description>LPFT Total Score is the number of points seen in the top 4 rows on the LPFT. Possible scores range from 0 (no points seen) to 35 (all points seen).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Marginal Reflex Distance (MRD) in the Study Eye</measure>
    <time_frame>Baseline Day 1 (Hour 0) and Day 1, Day 14, and Day 42</time_frame>
    <description>MRD is the distance from the center pupillary light reflex to the central margin of the upper eyelid. The MRD is measured from an external photograph.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Acquired Blepharoptosis</condition>
  <arm_group>
    <arm_group_label>RVL-1201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RVL-1201 Ophthalmic Solution 0.1% 1 drop per eye QD for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RVL-1201 Vehicle Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>RVL-1201 Ophthalmic Solution vehicle (placebo) 1 drop per eye QD for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RVL-1201</intervention_name>
    <description>RVL-1201 Ophthalmic Solution 0.1%</description>
    <arm_group_label>RVL-1201</arm_group_label>
    <other_name>Oxymetazoline Hydrochloride Ophthalmic Solution 0.1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RVL-1201 Vehicle Placebo</intervention_name>
    <description>RVL-1201 Vehicle Placebo</description>
    <arm_group_label>RVL-1201 Vehicle Placebo</arm_group_label>
    <other_name>RVL-1201 Ophthalmic Solution 0.1% Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects 18 years of age and older.&#xD;
&#xD;
          2. Presence of all of the following at Screening :&#xD;
&#xD;
             a. Loss on a reliable LPFT of ≥ 8 points in the top 2 rows (LPFT Eligibility Score);&#xD;
             subjects must see at least 9 total points in the top 4 rows (LPFT Total Score).&#xD;
&#xD;
             i. This criteria must be met at both the Visit 1 Hour 0 (V1H0) and Visit 1 Hour 6&#xD;
             (V1H6) LPFT assessments&#xD;
&#xD;
             ii. There must be ≤ 4 points of variance between the V1H0 and the V1H6 LPFT&#xD;
             Eligibility Score;; AND&#xD;
&#xD;
             b. The MRD, the distance from the central pupillary light reflex to the central margin&#xD;
             of the upper lid, must be ≤ 2 mm (no visible central pupillary light reflex defaults&#xD;
             to 0) in the same eye as Inclusion Criterion #2a&#xD;
&#xD;
             AND&#xD;
&#xD;
             c. Snellen visual acuity (VA) of 20/80 or better in the same eye as Inclusion Criteria&#xD;
             #2a and #2b.&#xD;
&#xD;
          3. Presence of all of the following at Baseline:&#xD;
&#xD;
             a. Loss on a reliable LPFT of ≥ 8 points in the top 2 rows (LPFT Eligibility Score) in&#xD;
             the same eye as Inclusion Criterion #2a; subjects must see at least 9 total points in&#xD;
             the top 4 rows (LPFT Total Score).&#xD;
&#xD;
             i. This criteria must be met at the Visit 2 Hour 0 (V2H0) LPFT assessment. ii. There&#xD;
             must be ≤ 4 points of variance between the V1H6 and the V2H0 LPFT Eligibility Score;&#xD;
&#xD;
             AND&#xD;
&#xD;
             b. Marginal Reflex Distance (MRD), the distance from the central pupillary light&#xD;
             reflex to the central margin of the upper lid, must be ≤ 2 mm (no visible central&#xD;
             pupillary light reflex defaults to 0) in the same eye as Inclusion Criterion #2a;&#xD;
&#xD;
             AND&#xD;
&#xD;
             c. Snellen VA of 20/80 or better in the same eye as Inclusion Criteria #2a and #2b.&#xD;
&#xD;
          4. Female subjects must be 1 year postmenopausal, surgically sterilized, or women of&#xD;
             childbearing potential with a negative urine pregnancy test at Visit 1. Women of&#xD;
             childbearing potential must use an acceptable form of contraception throughout the&#xD;
             study. Acceptable methods include the use of at least one of the following:&#xD;
             intrauterine (intrauterine device), hormonal (oral, injection, patch, implant, ring),&#xD;
             barrier with spermicide (condom, diaphragm), or abstinence.&#xD;
&#xD;
          5. Able to self-administer study medication or to have the study medication administered&#xD;
             by a caregiver throughout the study period.&#xD;
&#xD;
          6. Subjects must be able to understand and sign an IRB approved informed consent form&#xD;
             prior to participation in any study-related procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        In either eye&#xD;
&#xD;
          1. Congenital ptosis.&#xD;
&#xD;
          2. Presence of either of the following:&#xD;
&#xD;
               1. Pseudoptosis (upper eyelid dermatochalasis that overhangs the upper eyelid&#xD;
                  margin) or&#xD;
&#xD;
               2. Dermatochalasis that extends less than 3 mm above the upper eyelid margin.&#xD;
&#xD;
          3. Horner syndrome.&#xD;
&#xD;
          4. Marcus Gunn jaw winking syndrome.&#xD;
&#xD;
          5. Myasthenia gravis.&#xD;
&#xD;
          6. Mechanical ptosis, including ptosis due to orbital or lid tumor, cicatricial processes&#xD;
             affecting the movements of the upper lid, and enophthalmos.&#xD;
&#xD;
          7. Previous ptosis surgery (previous blepharoplasty [only] is allowed provided the&#xD;
             surgery took place &gt; 3 months prior to Visit 1).&#xD;
&#xD;
          8. Lid position affected by lid or conjunctival scarring.&#xD;
&#xD;
          9. Visual field loss from any cause other than ptosis.&#xD;
&#xD;
         10. History of herpes keratitis.&#xD;
&#xD;
         11. History of closed/narrow angle glaucoma (unless patent peripheral iridotomy has been&#xD;
             performed &gt; 3 months prior to Visit 1).&#xD;
&#xD;
         12. Periocular neurotoxin (eg, Botox, Xeomin, Dysport, Myobloc) injections within 3 months&#xD;
             prior to Visit 1 and during the study.&#xD;
&#xD;
         13. Topical application of bimatoprost (ie, Latisse®) to the eyelashes within 7 days prior&#xD;
             to Visit 1 and during the study.&#xD;
&#xD;
         14. Use of topical ophthalmic medications (including anti-allergy [eg, antihistamines],&#xD;
             dry eye [ie, Restasis®] and anti-inflammatory drugs [including nonsteroidal&#xD;
             anti-inflammatory drugs (NSAIDs) and steroids] other than the assigned study&#xD;
             medication within 7 days prior to Visit 1 and during the study. Topical ophthalmic&#xD;
             prostaglandin analogues for the treatment of elevated intraocular pressure are&#xD;
             permitted if dosed in the evening in accordance with the approved prescribing&#xD;
             information. All other topical antiglaucoma medications are prohibited&#xD;
&#xD;
         15. Intravitreal injections (eg, Lucentis®, Eylea®, Avastin®, Triesence®) within 7 days&#xD;
             prior to Visit 1 and during the study.&#xD;
&#xD;
         16. Current punctal plugs or placement of punctal plugs during the study.&#xD;
&#xD;
         17. Use of over the counter (OTC) vasoconstrictor/decongestant eye medication (eg, Visine®&#xD;
             L.R.®) or any ophthalmic or non-ophthalmic α adrenergic agonist including OTC products&#xD;
             (eg, Afrin®) at any time during the study; nonpreserved artificial tears are allowed.&#xD;
&#xD;
             General&#xD;
&#xD;
         18. Resting heart rate (HR) outside the normal range (60-100 beats per minute).&#xD;
&#xD;
         19. Hypertension with resting diastolic blood pressure (BP) &gt; 105 mm Hg.&#xD;
&#xD;
         20. Use of monoamine oxidase inhibitors (MAOIs; eg, isocarboxazid, phenelzine,&#xD;
             tranylcypromine) within 14 days prior to Visit 1 and during the study.&#xD;
&#xD;
         21. Advanced arteriosclerotic disease or history of cerebrovascular accident (CVA).&#xD;
&#xD;
         22. History of hyperthyroidism or thyroid eye disease (ie, exophthalmos, upper eyelid&#xD;
             retraction, diplopia secondary to extraocular muscle involvement). Hypothyroidism that&#xD;
             is controlled on medication is allowed.&#xD;
&#xD;
         23. Patients with diabetic retinopathy may not be enrolled. However, patients with insulin&#xD;
             dependent diabetes, diabetes requiring oral hypoglycemic drugs, or diet controlled&#xD;
             diabetes are allowed.&#xD;
&#xD;
         24. Pregnancy or lactation.&#xD;
&#xD;
         25. Diagnosed benign prostatic hypertrophy requiring medicinal therapy; previous&#xD;
             prostatectomy is allowed.&#xD;
&#xD;
         26. History of contact or systemic allergic reaction to oxymetazoline or other&#xD;
             sympathomimetic drugs (eg, phenylephrine, pseudoephedrine, ephedrine,&#xD;
             phenylpropanolamine, fepradinol, or methoxamine).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chuck Slonim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oculos Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 4, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <results_first_submitted>September 25, 2020</results_first_submitted>
  <results_first_submitted_qc>September 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2020</results_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharoptosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Planned sample size approx 150 subjects, 100 subjects in the RVL-1201 group, and 50 in the Vehicle group, to be enrolled at approx 20 clinical sites in the US.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>RVL-1201</title>
          <description>RVL-1201 (oxymetazoline hydrochloride) Ophthalmic Solution 0.1%, one drop each eye QD in the morning</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>Vehicle Placebo Ophthalmic Solution, one drop each eye QD in the morning</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subjects Randomized</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subjects Treated</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to Treat (ITT) Population</population>
      <group_list>
        <group group_id="B1">
          <title>RVL-1201</title>
          <description>RVL-1201 (oxymetazoline hydrochloride) Ophthalmic Solution 0.1%, one drop each eye QD in the morning</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>Vehicle Placebo Ophthalmic Solution, one drop each eye QD in the morning</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="12.22"/>
                    <measurement group_id="B2" value="63.2" spread="12.45"/>
                    <measurement group_id="B3" value="64.2" spread="12.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Median</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0"/>
                    <measurement group_id="B2" value="65.5"/>
                    <measurement group_id="B3" value="67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Intent to Treat (ITT) Population</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Iris Color OD (right eye) and Iris Color OS (left eye)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>OD/OS Blue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OD/OS Brown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OD/OS Green</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OD/OS Hazel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OD/OS Grey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OD/OS Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group</title>
        <description>LPFT Total Score is the number of points seen in the top 4 rows on the LPFT. Possible scores range from 0 (no points seen) to 35 (all points seen).</description>
        <time_frame>Mean change from Baseline (Day 1, Hour 0) compared with Day 1, Hour 6 and Day 14, Hour 2</time_frame>
        <population>Intent-to-Treat (ITT) population: randomized who received at least one dose (total of 140 subjects). Per-Protocol Population (PPP): ITT population with no major protocol deviations (total of 139 subjects). ITT analysis was conducted for the primary endpoint, with Last Observation Carried Forward (LOCF) for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>RVL-1201</title>
            <description>RVL-1201 (oxymetazoline hydrochloride) Ophthalmic Solution 0.1%, one drop each eye QD in the morning</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Ophthalmic Solution</title>
            <description>Vehicle Placebo Ophthalmic Solution, one drop each eye QD in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group</title>
          <description>LPFT Total Score is the number of points seen in the top 4 rows on the LPFT. Possible scores range from 0 (no points seen) to 35 (all points seen).</description>
          <population>Intent-to-Treat (ITT) population: randomized who received at least one dose (total of 140 subjects). Per-Protocol Population (PPP): ITT population with no major protocol deviations (total of 139 subjects). ITT analysis was conducted for the primary endpoint, with Last Observation Carried Forward (LOCF) for missing data.</population>
          <units>Points seen</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean LPFT-Day 1 Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="5.97"/>
                    <measurement group_id="O2" value="1.5" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean LPFT-Day 14 Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="5.04"/>
                    <measurement group_id="O2" value="2.2" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Two-sided t-test with treatment as a fixed factor and baseline score as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Marginal Reflex Distance (MRD) in the Study Eye</title>
        <description>MRD is the distance from the center pupillary light reflex to the central margin of the upper eyelid. The MRD is measured from an external photograph.</description>
        <time_frame>Baseline Day 1 (Hour 0) and Day 1, Day 14, and Day 42</time_frame>
        <population>Intent-to-Treat (ITT) population: randomized who received at least one dose (total of 140 subjects). Per-Protocol Population (PPP): ITT population with no major protocol deviations (total of 139 subjects). ITT analysis was conducted for the primary endpoint, with Last Observation Carried Forward (LOCF) for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>RVL-1201</title>
            <description>RVL-1201 (oxymetazoline hydrochloride) Ophthalmic Solution 0.1%, one drop each eye QD in the morning</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Ophthalmic Solution</title>
            <description>Vehicle Placebo Ophthalmic Solution, one drop each eye QD in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Marginal Reflex Distance (MRD) in the Study Eye</title>
          <description>MRD is the distance from the center pupillary light reflex to the central margin of the upper eyelid. The MRD is measured from an external photograph.</description>
          <population>Intent-to-Treat (ITT) population: randomized who received at least one dose (total of 140 subjects). Per-Protocol Population (PPP): ITT population with no major protocol deviations (total of 139 subjects). ITT analysis was conducted for the primary endpoint, with Last Observation Carried Forward (LOCF) for missing data.</population>
          <units>Millimeters (mm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Efficacy - Day 1, Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="0.924"/>
                    <measurement group_id="O2" value="0.67" spread="1.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary Efficacy - Day 14, Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.799"/>
                    <measurement group_id="O2" value="0.58" spread="0.975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Dose - Day 1, Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="0.776"/>
                    <measurement group_id="O2" value="0.50" spread="0.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Dose - Day 1, Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="0.958"/>
                    <measurement group_id="O2" value="0.70" spread="0.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Dose - Day 14, Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="0.856"/>
                    <measurement group_id="O2" value="0.70" spread="0.985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Dose - Day 14, Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.857"/>
                    <measurement group_id="O2" value="0.68" spread="1.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Dose - Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="1.036"/>
                    <measurement group_id="O2" value="0.79" spread="1.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>ANCOVA</method>
            <method_desc>Two-sided t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of treatment is 6 weeks (42 Days)</time_frame>
      <desc>Adverse Events (AEs) spontaneously reported by the subject and/or in response to open-ended questions from study personnel or revealed by observation and are recorded in the Case Report Form (CRF).</desc>
      <group_list>
        <group group_id="E1">
          <title>RVL-1201</title>
          <description>RVL-1201 (oxymetazoline hydrochloride) Ophthalmic Solution 0.1%, one drop each eye QD in the morning</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>Vehicle Placebo Ophthalmic Solution, one drop each eye QD in the morning</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Dictionary Version M</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrilation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Erythema of eyelid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Foreign body sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Vital dye staining cornea present</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director of Clinical Operations</name_or_title>
      <organization>RVL Pharmaceuticals, Inc.</organization>
      <phone>9088091423</phone>
      <email>mvelasco@osmotica.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

